A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements

Clin Lung Cancer. 2013 Sep;14(5):592-5. doi: 10.1016/j.cllc.2013.04.008. Epub 2013 Jun 27.
No abstract available

Keywords: Chemotherapy; Molecular subtypes; NSCLC; Pemetrexed; ROS1.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / mortality*
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Female
  • Gene Rearrangement*
  • Glutamates / therapeutic use*
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / mortality*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Pemetrexed
  • Prognosis
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Glutamates
  • Proto-Oncogene Proteins
  • Pemetrexed
  • Guanine
  • Protein-Tyrosine Kinases
  • ROS1 protein, human